United-Guardian, Inc.
UGConsumer DefensiveNASDAQHousehold & Personal Products
Scan Results
Daily timeframeUnited-Guardian, Inc. develops, manufactures, sells, and markets specialty cosmetic ingredients, pharmaceutical products, medical lubricants, and sexual wellness ingredients in the United States and internationally. With a market capitalization of $32.8M, it sits in micro-cap territory. The company offers cosmetic ingredients, including LUBRAJEL, a line of multifunctional hydrogel formulations for personal care and medical products; B-122, a powdered lubricant used in the manufacture of certain cosmetics, such as pressed powders, eyeliners, and rouges, as well as some industrial products; ORCHID COMPLEX, an oil-based extract of orchids; and LUBRASIL II SB, a special formulation of Lubrajel in which silicone oil incorporates into a Lubrajel base.
Market Cap
$32.8M
Beta
0.96
P/E (TTM)
12.97
P/E (Fwd)
—
EPS (TTM)
$0.55
EPS (Fwd)
—
ROE
21.3%
ROA
10.8%
Cash
$9.6M
Total Debt
$0
Free CF
$2.3M
52W Change
-16.0%
Annual Financials
Cash vs Debt
Where UG stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, UG finished 4.74% above its 150-day moving average ($6.75) and 9.10% above its 200-day moving average ($6.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is UG overbought or oversold?
At the September 3, 2026 close, UG's RSI(14) was 43.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
United-Guardian, Inc. reports $9.6M in cash and $0 in total debt. Annual free cash flow of $2.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 21.3% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 10.8% further supports the picture of efficient asset utilization. Revenue has pulled back from $12.7M (2022) to $10.5M (2025), a 17% decline worth watching.
As with any equity investment, UG carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing UG's risk profile alongside its fundamentals and technical indicators provides a more complete picture.